373 results match your criteria: "Okayama City Hospital.[Affiliation]"

Background And Aim: The study aims to develop a novel predictive model including the fibrosis (FIB)-3 index for hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) who achieved sustained virological response (SVR) with direct-acting antiviral (DAA) therapy.

Methods: This study included 2529 patients in whom HCV was eradicated with DAA therapy. The after DAA recommendation for surveillance (ADRES) score, which is based on sex, FIB-4 index, and α-fetoprotein, was used to predict HCC development.

View Article and Find Full Text PDF

Imaging of Perirenal and Intrarenal Lymphatic Vessels: Anatomy-based Approach.

Radiographics

March 2024

From the Department of Radiology (H.T., A.I., T.A.P., N.T.) and Department of Medicine, Division of Rheumatology (Y.S.), Mayo Clinic, 200 First St SW, Rochester, MN 55905; Department of Radiology, Okayama City Hospital, Okayama, Japan (T.T.); Department of Radiology, Jichi Medical University, Tochigi, Japan (S.M.); Department of Diagnostic and Interventional Radiology, University of Tsukuba, Ibaraki, Japan (M.M.); and Department of Radiology, Mayo Clinic, Scottsdale, Ariz (A.K.).

Article Synopsis
  • The lymphatic system includes lymphoid organs and vessels, but findings related to intrarenal and perirenal lymphatic vessels are not well-documented in radiology.
  • Lymphatic pathways in the renal cortex allow lymph to travel towards the hilum and capsular plexus, which can be visualized through contrast medium during CT urography, indicating possible complications like pyelolymphatic backflow.
  • Conditions like congenital renal lymphangiectasia and acquired renal complications can affect imaging post-kidney transplant, with distinct fluid patterns in the urinary tract indicating issues like chyluria, highlighting the importance of understanding lymphatic pathways for effective cancer management.
View Article and Find Full Text PDF

We analyzed the correlation between the duration of electroencephalogram (EEG) recovery and histological outcome in rats in the acute stage of subarachnoid hemorrhage (SAH) to find a new predictor of the subsequent outcome. SAH was induced in eight rats by cisternal blood injection, and the duration of cortical depolarization was measured. EEG power spectrums were given by time frequency analysis, and histology was evaluated.

View Article and Find Full Text PDF

Endoscopic and clinical features of gastric emphysema.

Sci Rep

January 2024

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Article Synopsis
  • Gastric emphysema is a rare condition involving gas in the stomach's walls without infection, often reported in single cases; this study analyzes a larger cohort of 45 patients to understand its features and outcomes.
  • The average age of patients diagnosed was 68.6 years, with common underlying issues including nasogastric tube placement, diabetes, and malignancies.
  • Most patients were treated conservatively, leading to favorable recovery in 35 cases, while 7 patients died soon after diagnosis; endoscopic evaluations revealed specific mucosal patterns associated with the condition, marking this as the first detailed report on such findings in English literature.
View Article and Find Full Text PDF

Background: Data concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing.

Objective: This analysis aimed to evaluate the efficacy and safety of lenvatinib in a large cohort of very old patients (≥ 80 years) with unresectable HCC.

Patients And Methods: The study was conducted on a cohort of 1325 patients from 46 centers in four Western and Eastern countries (Italy, Germany, Japan, and the Republic of Korea) who were undergoing first-line treatment with lenvatinib between July 2010 and February 2022.

View Article and Find Full Text PDF
Article Synopsis
  • Cell therapy using MultiStem, a multipotent progenitor cell product from bone marrow, is being evaluated for its potential to treat ischemic stroke, which involves a lack of blood flow to the brain.
  • The TREASURE trial, a double-blind, placebo-controlled study conducted at 44 centers in Japan, aimed to determine the safety and efficacy of MultiStem when given to patients within 18-36 hours of stroke onset.
  • Key outcomes were measured through various scales at 90 and 365 days post-treatment, assessing safety and overall recovery, with the study involving 206 patients (104 receiving MultiStem and 102 receiving placebo).
View Article and Find Full Text PDF

An immunocompetent case of chronic pulmonary aspergillosis caused by Aspergillusviridinutans.

Respir Investig

January 2024

Department of Allergy and Respiratory Medicine, National Hospital Organization, Minami Okayama Medical Center, 4066 Hayashima, Hayashima-cho Tsukubo-gun, Okayama, 701-0304, Japan.

We encountered an extremely rare immunocompetent case of chronic pulmonary aspergillosis (CPA) caused by Aspergillus viridinutans. A 74-year-old woman was admitted with fever and hemoptysis. Chest computed tomography revealed a nodule in the left upper lobe.

View Article and Find Full Text PDF

Purpose: Radiological tumor burden has been reported to be prognostic in many malignancies in the immunotherapy era, yet whether it is prognostic in patients with metastatic urothelial carcinoma (mUC) treated with pembrolizumab remains uninvestigated. We sought to assess the predictive and prognostic value of radiological tumor burden in patients with mUC.

Methods: We performed a retrospective analysis of 308 patients with mUC treated with pembrolizumab.

View Article and Find Full Text PDF

Introduction: Because of recent developments in treatments for hepatocellular carcinoma (HCC), methods for determining suitable therapy for initial or recurrent HCC have become important. This study used artificial intelligence (AI) findings to establish a system for predicting prognosis of HCC patients at time of reoccurrence based on clinical data as a reference for selection of treatment modalities.

Methods: As a training cohort, 5,701 observations obtained at the initial and each subsequent treatment for recurrence from 1,985 HCC patients at a single center from 2000 to 2021 were used.

View Article and Find Full Text PDF

Background: In 2016, the DANISH study reported negative results regarding the efficacy of implantable cardioverter-defibrillators (ICDs) in patients with non-ischemic cardiomyopathy (NICM) and reduced left ventricular ejection fraction (LVEF). In this study we determined the efficacy of using ICDs for primary prophylaxis in patients with NICM.

Methods and results: We selected 1,274 patients with underlying cardiac disease who were enrolled in the Nippon Storm Study.

View Article and Find Full Text PDF

Malrotation of tibial fractures after intramedullary nailing remains an unsolved problem. The incidence of malrotation >10° on computer tomography (CT) measurements has been high in cases of tibial shaft fractures. We aimed to assess the accuracy of a novel method for the measurement of tibial rotation using lateral axis views of the C-arm, to prevent postoperative malrotation.

View Article and Find Full Text PDF

Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first-line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison of the two regimens has been performed in randomized clinical trials, making the identification of baseline differential predictors of response of major relevance to tailor the best therapeutic option to each patient. Baseline clinical and laboratory characteristics of real-world AB-treated HCC patients were analyzed in uni- and multivariate analyses to find potential prognostic factors of overall survival (OS).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effects of two treatments, atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN), on liver function in patients with hepatocellular carcinoma.
  • A total of 526 patients who received Atez/Bev and 731 who received LEN were analyzed, with 324 patients in each group after matching, using a model to evaluate liver health changes over time.
  • Both treatments led to similar deterioration in liver function scores, with significant worsening observed in LEN-treated patients who were at an advanced cancer stage or received a full dose, highlighting the need for caution in these cases.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effectiveness of two treatments, atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN), for elderly patients (80 years and older) with advanced hepatocellular carcinoma (HCC).
  • A total of 262 patients were analyzed, with similar age and gender distributions in both treatment groups, showing comparable objective response rates and overall survival.
  • Atez/Bev demonstrated a higher incidence of postprogression treatment and a lower discontinuation rate due to side effects, suggesting it could be a viable first-line option for treating HCC in elderly patients.
View Article and Find Full Text PDF

Background: EUS-FNA/B for pancreatic ductal adenocarcinoma (PDAC) is generally considered to be safe; however, while the incidence is low, there are occurrences of complications. Among these complications, there are serious ones like needle tract seeding (NTS), and it is not known than which types of tumors have the risks of EUS-FNA/B complications. This study aimed to evaluate the risk of EUS-FNA/B complications in patients with PDAC, focusing on morphological features.

View Article and Find Full Text PDF

To determine the endoscopic and clinical features of localized gastric amyloid light-chain (AL) amyloidosis, we retrospectively examined the characteristics of nine patients (eight men and one woman) encountered by the hospitals in our network. Lesions were predominantly flat and depressed with surface vascular dilatation (n=5); others were characterized by subepithelial lesions (n=2), mucosal color change (n=1), and a mass-like morphology with swollen mucosal folds (n=1). Colonoscopy (n=7), video capsule enteroscopy (n=2), serum (n=5) and urine immunoelectrophoresis (n=4), and bone marrow examination (n=3) were performed to exclude involvement of organs other than the stomach.

View Article and Find Full Text PDF

Using a Collaborative Action Research model, our research team established a one-month clinical resident training program for first- and second-year clinical residents. We created and implemented an assessment rubric to assess the residents' progress toward independent practice in surgery, and thereby, to evaluate the program itself. The program included training in three areas: basic techniques and procedures in the operating room, surgical ward management, and academic activities.

View Article and Find Full Text PDF

A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection.

PLoS One

October 2023

Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

Background: Some COVID-19 patients develop life-threatening disease accompanied by severe pneumonitis. Teprenone induces expression of heat-shock proteins (HSPs) that protect against interstitial pneumonia in preclinical models. We explored whether teprenone prevented worsening of COVID-19 infections.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to compare the effectiveness of two treatments, atezolizumab plus bevacizumab (Atezo/Bev) and lenvatinib (LEN), in patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer (BCLC) staging system.
  • - A total of 358 patients were evaluated, with those receiving Atezo/Bev experiencing a median progression-free survival (PFS) of 10.8 months, while those receiving LEN had a PFS of 7.3 months, indicating better outcomes for Atezo/Bev.
  • - Overall, the findings suggest that Atezo/Bev as the first-line treatment leads to significantly longer progression
View Article and Find Full Text PDF

Recent Advancements for the Treatment of Hepatocellular Carcinoma.

Cancers (Basel)

September 2023

Department of Gastroenterology, Okayama City Hospital, 3-20-1, Kitanagase-omotemachi, Kita-ku, Okayama 700-8557, Japan.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and is currently one of the most common cancers [...

View Article and Find Full Text PDF